Japan’s Kyowa Hakko Sells Amgen Drug Rights For $520 Million
This article was originally published in PharmAsia News
Kyowa Hakko Kogyo has agreed to sell the rights to a key cancer and inflammation drug it is developing to Amgen for $520 million. The U.S. biotech is to pay Japan's Kyowa $100 million up-front and the rest during development of humanized monoclonal antibody KW-0761. Under the arrangement, Kyowa subsidiary Kirin Holdings is to retain rights to develop and sell the drug in Japan, South Korea, China and Taiwan, and Amgen elsewhere in the world. The drug is in Phase I trials on lymphoma patients. (Click here for more
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.